TRIMTECH Therapeutics
trimtechtx.bsky.social
TRIMTECH Therapeutics
@trimtechtx.bsky.social
Our therapeutic approach is based on pioneering research into TRIM21, an underexploited but widely expressed ubiquitin ligase, that can be directed to treat protein aggregation disorders and bring therapeutic benefits.
Today is the International Day of Women and Girls in Science, observed each year on February 11.

At TRIMTECH, we’re proud that our team includes so many talented women scientists at all levels of the organisation whose expertise, dedication, and impact drive our work forward every day.
February 11, 2026 at 12:25 PM
We have been shortlisted for the One Nucleus Awards 2026, in the ‘Best Therapeutic R&D Programme of the Year’ category!

Visit our website to learn more about our work: trimtechtherapeutics.com/science/
February 10, 2026 at 1:47 PM
Join TRIMTECH Scientist, Jonathan Benn, at the next Cambridge New Therapeutics Forum and learn more about our aggregate-selective targeted protein degrader programme, offering a small molecule approach to combat neurodegenerative diseases.

Register here: www.eventbrite.co.uk/e/advances-i...
January 20, 2026 at 1:11 PM
JPM Healthcare Conference Week 2026 is well underway in San Francisco!

Our CEO Nicki Thompson presented at the Cambridge x London Life Sciences Showcase, part of RESI JPM Healthcare Week 2026.
January 14, 2026 at 3:24 PM
Happy New Year! We’re kicking off 2026 in San Francisco at Sachs’ 9th Annual Neuroscience Innovation Forum and JPM Healthcare Conference Week.

Schedule a meeting 📩 trimtechtherapeutics.com/contact/
January 6, 2026 at 12:00 PM
From all of us at TRIMTECH, happy holidays! 🎄

We’re incredibly proud of what our team has achieved and look forward to another exciting year ahead!
December 19, 2025 at 12:47 PM
Delighted to welcome Alison Lawton as Chair of our Board. With 35+ years in global biotech and pharma, she brings deep development, operational and leadership experience to support TRIMTECH’s next stage of growth: shorturl.at/xXXbC
December 2, 2025 at 9:25 AM
Our academic co-founders have published in Nature Communications - detailing the science behind TRIMTECH’s TRIMTAC® degraders. Congrats to Will, Leo, Dean, Jonathan, and all collaborators advancing state-selective protein degradation: www.nature.com/articles/s41...
November 28, 2025 at 9:36 AM
We’re absolutely delighted to have been awarded ‘Seed Raise of the Year’ at last night’s LSX European Lifestars Awards!
November 18, 2025 at 11:17 AM
Our team will be in London during Jefferies Global Healthcare Conference Week, kicking off discussions across the global healthcare sector as part of London Life Sciences Week!
November 13, 2025 at 11:45 AM
We’re delighted to welcome Dr. Mike Hutton to our SAB!

Mike joins Prof. Alessio Ciulli FRS and Dr. Adam Gilbert in advancing our mission to develop novel therapeutics that target protein aggregates in neurodegenerative diseases.

Read more: trimtechtherapeutics.com/trimtech-the...
November 11, 2025 at 9:20 AM
Meet our Senior Director of Chemistry, Dr Andrea Testa, and discover his journey in targeted protein degradation research in this blog: trimtechtherapeutics.com/meet-the-tea...
November 5, 2025 at 10:44 AM
We’ll be in Barcelona for the 2nd Annual Drug Discovery Chemistry Europe. Catch our Head of Exploratory Biology, Dr Dean Clift, on Day 1 in the Next-Gen Degraders & Molecular Glues track

➡️https://www.drugdiscoverychemistry.com/europe/degraders-molecular-glues
November 4, 2025 at 1:21 PM
CEO Dr Nicki Thompson is in Boston for the 8th Annual TPD and Induced Proximity Summit.

Catch her sessions today to learn more about TRIMTECH’s work in TPD.
October 30, 2025 at 1:12 PM
We’ve been awarded ‘Start-up of the Year’ at the annual TPD & Induced Proximity Awards 🏆

Learn more about our pipeline of small-molecule, aggregate-selective, targeted protein degraders for the treatment of neurodegenerative diseases: trimtechtherapeutics.com/science/
October 30, 2025 at 10:54 AM
Only a few weeks to go until the 8th Annual TPD and Induced Proximity Summit!

Learn more about our pipeline of small-molecule, aggregate-selective, targeted protein degraders for the treatment of neurodegenerative diseases: trimtechtherapeutics.com/science/
October 16, 2025 at 11:02 AM
Dr Damian Crowther, Head of Research, will be at Alzheimer’s Research UK’s Drug Discovery Alliance Networking Event, giving the plenary session on ‘Drug Discovery and the Future of Drug Development’.

Learn more: www.alzheimersresearchuk.org/about-us/how...
October 7, 2025 at 3:29 PM
Our CEO, Nicki Thompson, participated in a panel discussion on ‘Innovations in Protein Degradation in the Biotech Sector’ at Discovery on Target in Boston, highlighting how novel degrader modalities are driving innovation and enabling pursuit of challenging targets.

#BostonDOT #TPD
September 25, 2025 at 12:30 PM
We’re incredibly proud to be one of Fierce Biotech’s #Fierce15 – testament to our approach and the milestones our team has already achieved!

Our goal is to develop cost-effective, disease-modifying treatments for common, aggregation-driven diseases.

More: shorturl.at/IRTJO
September 22, 2025 at 2:30 PM
21 Sep is #WorldAlzheimersDay, part of #WorldAlzheimersMonth.

Over 55M people live with dementias, yet the need for cost-effective, disease-modifying treatments remains critical.

TRIMTECH is advancing small molecule, aggregate-selective, targeted protein degraders 👉 trimtechtherapeutics.com
September 19, 2025 at 12:10 PM
Next week our CEO Nicki Thompson will be in Boston for Discovery on Target.

Arrange a meeting: trimtechtherapeutics.com/contact/

#BostonDOT
September 18, 2025 at 11:59 AM
A busy couple of weeks ahead for the TRIMTECH team – scroll through to see where we’ll be this September ➡️
September 12, 2025 at 2:20 PM
EFMC-ASMC 2025 is well underway in Portugal!

Join Senior Director of Chemistry, Dr Andrea Testa, at the 12th EFMC Young Medicinal Chemists’ Symposium, organised with the Young Scientist Network.

Get in touch ➡️ trimtechtherapeutics.com/contact/
September 4, 2025 at 3:06 PM
We’ve been selected as a finalist for ‘Seed Raise of the Year’ at the LSX European Lifestars Awards. Earlier this year we closed a $31M (£25M) seed round, to support development of our protein degrader pipeline ➡️ informaconnect.com/european-lif...
September 3, 2025 at 3:27 PM
Excited to introduce our SAB! Professor Alessio Ciulli (SAB Chair) and Dr Adam Gilbert. Both are global leaders in targeted protein degradation, providing strategic guidance to advance our TRIMTAC and TRIMGLUE degraders and small molecule therapeutic pipeline.

More: shorturl.at/f76pR
September 2, 2025 at 9:22 AM